Ontario's MoH Approves Rituxan's Reimbursement For Pemphigus Vulgaris

The Government of Ontario's Ministry of Health (MoH) and Long-Term Care has decided to fund Roche's Rituxan (rituximab) for the treatment of pemphigus vulgaris through the Ontario Public Drug Programs - Exceptional Access Program.

The Canadian Pemphigus and Pemphigoid Foundation was involved in this process, and has encouraged other provinces and territories to follow the Government of Ontario's lead.

This article is tagged to:
Sector: Pharmaceuticals & Healthcare
Geography: Canada

Access all of our latest analysis, data and forecasts - request a trial